Moreover, it is suggested that RASSF1A inhibits malignant phenotypes by repressing PDGFB expression in a YAP1-dependent manner and PDGFB could serve as the potential therapeutic agent for metastatic NPC treatment [55]. Here, RASSF1 is linked to nasopharyngeal carcinoma.